Guggenheim Forecasts Strong Price Appreciation for uniQure (NASDAQ:QURE) Stock

Key Points

• Guggenheim has raised its price target for uniQure (NASDAQ:QURE) from $28.00 to $95.00, predicting a potential upside of 100% from the stock's previous close, while maintaining a "buy" rating.
• Several analysts have also provided optimistic ratings, with target prices ranging from $65.00 to $76.00 and a current consensus rating of "Moderate Buy".
• uniQure reported a net loss of $0.69 EPS for the last quarter, exceeding expectations, with revenues of $5.26 million, and is developing treatments for rare diseases including hemophilia B and Huntington's disease.

uniQure (NASDAQ:QURE - Get Free Report) had its price objective hoisted by equities researchers at Guggenheim from $28.00 to $95.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a "buy" rating on the biotechnology company's stock. Guggenheim's target price would indicate a potential upside of 100.00% from the stock's previous close.

Several other analysts also recently issued reports on QURE. HC Wainwright restated a "buy" rating and set a $70.00 price objective on shares of uniQure in a report on Wednesday. Stifel Nicolaus boosted their price objective on uniQure from $30.00 to $65.00 and gave the stock a "buy" rating in a report on Wednesday. Chardan Capital upped their target price on uniQure from $35.00 to $76.00 and gave the company a "buy" rating in a report on Thursday. Wall Street Zen upgraded uniQure from a "sell" rating to a "hold" rating in a report on Saturday, August 2nd. Finally, Leerink Partners upped their target price on uniQure from $48.00 to $68.00 and gave the company an "outperform" rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $55.45.

uniQure Price Performance

NASDAQ QURE opened at $47.50 on Thursday. The stock's 50-day moving average price is $15.90 and its two-hundred day moving average price is $14.32. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The company has a market cap of $2.61 billion, a PE ratio of -12.12 and a beta of 0.14. uniQure has a 1 year low of $4.45 and a 1 year high of $51.21.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.20. The firm had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. On average, analysts predict that uniQure will post -3.75 EPS for the current year.

Hedge Funds Weigh In On uniQure

Hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC boosted its position in uniQure by 358.0% during the second quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 5,538 shares during the period. Mraz Amerine & Associates Inc. bought a new position in uniQure in the first quarter worth $106,000. KLP Kapitalforvaltning AS bought a new position in uniQure in the second quarter worth $117,000. Teacher Retirement System of Texas bought a new position in uniQure in the second quarter worth $151,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of uniQure during the first quarter valued at $152,000. Institutional investors and hedge funds own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.